| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2048150 | FEBS Letters | 2011 | 8 Pages |
Peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-regulated nuclear hormone receptor, plays critical roles in metabolism and adipogenesis. PPARγ ligands such as thiazolidinediones (TZDs) exert insulin sensitizing and anti-inflammatory effects primarily through action on adipocytes, and are thus widely used to treat metabolic syndrome, especially type II diabetes. A number of PPARγ interacting partners have been identified, many of which are known epigenetic regulators, including enzymes for histone acetylation/deacetylation and histone methylation/demethylation. However, their functional roles in the PPARγ transcriptional pathway are not well defined. Recent advances in ChIP-based and deep sequencing technology are revealing previously underappreciated epigenomic mechanisms and therapeutic potentials of this nuclear receptor pathway.
► Anti-diabetic TZD class of drugs targets PPARγ primarily through effects in adipocytes. ► Many PPARγ interacting proteins possess epigenetic activities. ► Recent technical advance in ChIP-based whole genome analysis uncovers novel epigenomic mechanisms. ► Understanding precise epigenetic regulation of PPARγ should facilitate potential therapeutic approaches.
